Latest News

More Illnesses Possible Related Linked to Counterfeit Botulinum Toxin Reported


 

FROM THE MMWR

In March 2024, four women in Tennessee and three in New York City fell ill after receiving botulinum neurotoxin (BoNT) injections in nonmedical settings, and four of the women required hospitalization — two in the intensive care unit. None of the cases required intubation, according to an announcement of an investigation into these reports in by the Centers for Disease Control and Prevention (CDC).

The report, published online in the Morbidity and Mortality Weekly Report, notes that the four patients in Tennessee received counterfeit BoNT, while product information was not available for the three cases in New York City. “However, one person reported paying less than US wholesale acquisition cost for the administered product, and another reported that the product had been purchased overseas,” the authors of the report wrote. The development underscores that BoNT injections “should be administered only by licensed and trained providers using recommended doses of FDA [Food and Drug Admininstration]-approved products.”

This report follows a CDC advisory published in April 2024 of at least 22 people from 11 states who reported serious reactions after receiving botulinum toxin injections from unlicensed or untrained individuals or in nonhealthcare settings, such as homes and spas.

The median age of the women in the July report was 48 years, and signs and symptoms included ptosis, dry mouth, dysphagia, shortness of breath, and weakness. Onset occurred between February 23 and March 7, 2024.

“This investigation did not determine why these illnesses occurred after cosmetic BoNT injections; potential reasons might include use of counterfeit BoNT, which might be more potent or contain harmful additional ingredients or higher susceptibility to BoNT effects among some persons,” the investigators wrote. They recommended further studies to describe the clinical spectrum of cosmetic BoNT injection effects such as severity of signs and symptoms.

For cases of suspected systemic botulism, the CDC recommends calling the local or state health department for consultation and antitoxin release (as well as information on reporting adverse events). Alternatively, the 24/7 phone number for the CDC clinical botulism service is 770-488-7100.

A version of this article first appeared on Medscape.com.

Recommended Reading

Copaxone lipoatrophy far more common than reported
MDedge Neurology
Hand washing and hand sanitizer on the skin and COVID-19 infection risk
MDedge Neurology
Guidance issued on COVID vaccine use in patients with dermal fillers
MDedge Neurology
Photobiomodulation: Evaluation in a wide range of medical specialties underway
MDedge Neurology
Ophthalmologist who developed medical botox dies at 89
MDedge Neurology
Can lasers be used to measure nerve sensitivity in the skin?
MDedge Neurology
FDA to step up oversight of cosmetics, assess ‘forever chemicals’
MDedge Neurology
Public Citizen seeks stronger warning for Botox, related products
MDedge Neurology
CDC Investigating Adverse Events Related to Counterfeit, Mishandled Botulinum Toxin
MDedge Neurology
Association Calls For Increased Oversight in Response to Reports of Possibly Counterfeit Botulinum Toxin
MDedge Neurology